Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.

Molecular cancer therapeutics - 1 Nov 2020

Kashima Kenji, Kawauchi Hiroki, Tanimura Hiromi, Tachibana Yukako, Chiba Takashi, Torizawa Takuya, Sakamoto Hiroshi

Abstract excerpt

Osimertinib is the only EGFR-tyrosine kinase inhibitor (TKI) capable of overcoming EGFR-T790M-mutated NSCLC, but osimertinib-resistant EGFR triple mutations (Del19/T790M/C797S or L858R/T790M/C797S) have been reported. Although allosteric EGFR TKIs (e.g., EAI-045) that potentially overcome L858R/T790M/C797S have been identified, there are no effective inhibitors against Del19/T790M/C797S. In this study, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Binding, Competitive

Share to Cell Survival

Share to Molecular Docking Simulation

Share to Molecular Dynamics Simulation

Share to Structure-Activity Relationship

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 32943545
DOI: 10.1158/1535-7163.MCT-20-0229

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.PMID 32943545Read ↗

HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.Semantic proximity Read ↗

Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19/T790M/C797S) mutation.Semantic proximity Read ↗

Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors.Semantic proximity Read ↗

Design, synthesis and biological evaluation of 2,4,5-trisubstituted 7H-Pyrrolo[2,3-d]pyrimidine derivatives as potent EGFR tyrosine kinase inhibitors against the C797S acquired resistance mutation.Semantic proximity Read ↗

CZC54252 overcomes Osimertinib resistance by targeting EGFRC797S mutations.Semantic proximity Read ↗

Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance.Semantic proximity Read ↗

Design, Synthesis, and Biological Evaluation of Novel Diaminopyrimidine Macrocycles as Fourth Generation Reversible EGFR Inhibitors That Overcome Clinical Resistance to Osimertinib Mediated by C797S Mutation.Semantic proximity Read ↗

Pan-EGFR inhibitor targeting EGFR 19del, L858R/T790M and C797S triple-mutations: Design, synthesis, and pharmacological evaluation.Semantic proximity Read ↗

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.Semantic proximity Read ↗

LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.Semantic proximity Read ↗

p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.